Advertisement

Topics

Top five promising drugs Phase III (November 2013)

02:19 EDT 23rd August 2017 | BioPortfolio

THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS

DRUG DISEASE COMPANY
BMN-673 BRCA-mutation-positive breast cancer Biomarin Pharmaceuticals
eravacycline Complicated intra-abdominal infection Tetraphase Pharmaceuticals
ACAM-CDIFF™ Clostridium difficile infection Sanofi
Fovista™ Wet age-related macular degeneration Ophthotech
REG-1 Thrombosis in percutaneous coronary intervention Regardo Biosciences

 

 

 

 

 

Source: Thomson Reuters Cortellis Competitive Intelligence.

  
  
 
  
  
 

Quick Search
Advertisement
 

review and buy Top five promising drugs Phase III (November 2013) market research data and corporate reports here